-
Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium
Friday, October 9, 2015 - 8:01am | 231Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted for presentation at the North American Neuroendocrine Tumor Society annual symposium to be held from October 15-17, in Austin, Texas. In...
-
Benzinga's Volume Movers
Thursday, October 8, 2015 - 10:28am | 198Journal Media Group Inc (NYSE: JMG) shares climbed 43.61 percent to $11.92. The volume of Journal Media shares traded was 500 percent higher than normal. Gannett Co Inc. (NYSE: GCI) agreed to acquire Journal Media for $280 million. Biomed Realty Trust Inc (NYSE: BMR) surged 8.71 percent to $23...
-
Morning Market Gainers
Thursday, October 8, 2015 - 9:43am | 398WaferGen Bio-systems, Inc. (NASDAQ: WGBS) shares gained 50.66 percent to $2.29 on strong revenue guidance for the third quarter. Journal Media Group Inc (NYSE: JMG) shares jumped 42.17 percent to $11.80 after Gannett Co Inc. (NYSE: GCI) agreed to acquire Journal Media for $280 million. Mistras...
-
Benzinga's Top #PreMarket Gainers
Thursday, October 8, 2015 - 8:11am | 176Journal Media Group Inc (NYSE: JMG) shares rose 42.34 percent to $11.80 in pre-market trading after Gannett Co Inc. (NYSE: GCI) agreed to acquire Journal Media for $280 million. Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares climbed 14.51 percent to $44.58 in pre-market trading as the...
-
Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
Thursday, October 8, 2015 - 6:31am | 729Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial...
-
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689
Tuesday, September 29, 2015 - 9:02am | 142Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has expanded its global license and supply agreements with SAGE Therapeutics (SAGE) to now also cover the use of Captisol® in the development and commercialization of SAGE-689. Under the terms of the license, Ligand received a...
-
US Stock Futures Rise Ahead Of Housing, Consumer Confidence Data
Tuesday, September 29, 2015 - 7:10am | 449Pre-open movers US stock futures traded higher in early pre-market trade. The S&P/Case-Shiller home price index for July will be released at 9:00 a.m. ET, while the Conference Board's consumer confidence report for September will be released at 10:00 a.m. ET. Data on farm prices for September...
-
Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care
Tuesday, September 29, 2015 - 6:03am | 939Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog (SSA) therapy, the current standard of care, according to data from the Phase 3...
-
AbbVie Offers Plans to Proceed to Phase 3 Evaluation of Elagolix
Wednesday, September 16, 2015 - 9:01am | 590AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy compared to placebo. The trial was conducted in women with...
-
La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
Friday, September 11, 2015 - 8:00am | 462La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the European Medicines Agency (EMA) Committee for...
-
Stocks Hitting 52-Week Highs
Tuesday, September 8, 2015 - 10:09am | 156La Jolla Pharmaceutical Company (NASDAQ: LJPC) shares touched a new 52-week high of $36.83. La Jolla Pharmaceutical shares have jumped 246.65 percent over the past 52 weeks, while the S&P 500 index has declined 4.01 percent in the same period. Builders FirstSource, Inc. (NASDAQ: BLDR) shares...
-
Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress
Wednesday, August 26, 2015 - 8:02am | 168Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from its pivotal TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted as a late-breaking presentation at the European Cancer Congress, which will be held September 25–29 in Vienna, Austria. Telotristat...
-
Benzinga's Top Downgrades
Monday, August 10, 2015 - 9:34am | 338Analysts at Raymond James downgraded Intuit Inc. (NASDAQ: INTU) from Outperform to Market Perform. Intuit shares closed at $105.44 on Friday. Oppenheimer downgraded Marathon Oil Corporation (NYSE: MRO) from Outperform to Perform. Marathon Oil shares closed at $18.40 on Friday. Analysts at JP...
-
Benzinga's Volume Movers
Monday, August 3, 2015 - 10:24am | 180Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares climbed 47.87 percent to $12.48. The volume of Lexicon Pharmaceuticals shares traded was 5401 percent higher than normal. Lexicon Pharmaceuticals reported that its TELESTAR Phase 3 clinical trial met primary endpoint. Partnerre Ltd (NYSE: PRE)...
-
Stocks Hitting 52-Week Highs
Monday, August 3, 2015 - 10:07am | 141Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares gained 53.32 percent to reach a new 52-week high of $12.94 as TELESTAR Phase 3 clinical trial met primary endpoint. Insmed Incorporated (NASDAQ: INSM) shares touched a new 52-week high of $27.77. Insmed is expected to report Q2 financial results...